PRESENTATION

Q1 2025 — Presentation

Q1 2025PDF · 15 pages211 KB
Elevance Health
1Q 2025 Earnings Presentation
April 22, 2025

-- 1 of 15 --

22
The Value We Deliver
We advance whole health through innovative solutions that integrate physical,
behavioral, and social care to achieve our purpose of improving the health of humanity
For Consumers
Simple, Affordable, and Accessible Health Care
1. 	Simplifying healthcare through enhanced digital
capabilities that personalize member experiences
2. 	Affordability at the core of our innovative plan designs
3. 	Accessibility through advocacy and data driven solutions
that elevate whole health
1. 	Differentiated clinical partnerships built on shared
expertise and coordinated care
2. 	Advanced clinical collaboration and value-based care
3. 	Aligned business partner through digital tools
that enhance information exchange and reduce
administrative burden
For Care Providers
Deepen Clinical and Business Partnerships

-- 2 of 15 --

3
Key Highlights
• 	Elevance Health first quarter results were consistent with expectations
• 	Operating revenue of $48.8B grew more than 15%
• 	Medical loss ratio of 86.4% increased 80 bps
• 	Adjusted diluted EPS1 of $11.97 grew more than 10%
• 	Returned $1.3B to shareholders through dividends and share repurchases
1Q 2025 Results
1
• 	Reaffirm adjusted diluted EPS1 to be in the range of $34.15 – $34.85
• 	While early in the year, utilization patterns have developed in line with our guidance ranges
• 	Expect slightly more than 60% of adjusted diluted EPS to be realized in the first half of 2025
2025 Outlook
2
• 	Elevance Health has made significant investments to transform the healthcare experience for the members,
care providers, and communities we serve
• 	Our solutions, such as patient advocacy, HealthOS, and our value-based oncology care model, are delivering
a more personalized experience, improved health outcomes, and lower costs
• 	We are advancing our long-term strategy, with progress on rate alignment in Medicaid, disciplined execution
in Medicare Advantage, sustained Commercial momentum, and continued expansion in Carelon
• 	Ensure long-term, sustainable growth by leveraging the complementary strengths and diverse earnings
capabilities of our enterprise portfolio
Strategic Focus Areas
3
1. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 3 of 15 --

44
Key Highlights
• 	Elevance Health first quarter results
were consistent with expectations
• 	Operating revenue of $48.8B grew
15.4%, attributable to higher premium
yields in Health Benefits, acquisitions
completed in 2024, increased Medicare
Advantage and Individual ACA
membership (partially offset by
Medicaid membership attrition), and
CarelonRx product revenue
• 	Medical loss ratio of 86.4% reflects
higher Medicaid cost trends partly
offset by out of period premium taxes
• 	Adjusted operating expense was 10.7%,
an improvement of 60 bps, reflecting
our ongoing commitment to disciplined
cost management
• 	Operating cash flow of $1.0B reflects
timing-related working capital impacts
1Q 2025 Results
Change (%/bps)	1Q 2024	1Q 2025	Elevance Health
15.4%	$42.3B	$48.8B	Operating Revenue 1
80 bps	85.6%	86.4%	Medical Loss Ratio
(60) bps	11.3%	10.7%	Adjusted Operating Expense Ratio1,2
4.1%	$3.1B	$3.3B	Adjusted Operating Gain1,2
(70) bps	7.4%	6.7%	Adjusted Operating Margin 1,2
26.9%	$465M	$590M	Net Investment Income
10.5%	$10.83	$11.97	Adjusted Diluted EPS 2
($1.0B)	$2.0B	$1.0B	Operating Cash Flow
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 4 of 15 --

55
Key Highlights
• 	Health Benefits first quarter results
reflect strong revenue growth; while
early in the year, utilization trends
were consistent with our expectations
• 	Operating revenue grew 11.2% year
over year, driven by higher premium
yields and growth in Medicare
Advantage and Individual ACA
membership
• 	Adjusted operating margin of 5.4%
declined by 80 bps, due to higher
Medicaid cost trend, partly offset by
operating efficiencies
• 	Membership of 45.8M reflects Medicaid
redeterminations, offset by targeted
growth and higher retention rates in
Medicare Advantage, and increases in
Commercial risk-based membership
Change (%/bps)	1Q 2024	1Q 2025	Health Benefits
11.2%	$37.3B	$41.4B	Operating Revenue 1
(3.7%)	$2.3B	$2.2B	Adjusted Operating Gain1,2
(80) bps	6.2%	5.4%	Adjusted Operating Margin 1,2
(0.5%)	46.0M	45.8M	Membership
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “Reportable Segment Highlight Details” on slide 14 herein.
Health Benefits
1Q 2025 Results

-- 5 of 15 --

66
Key Highlights
• 	Robust revenue growth driven by the
scaling of innovative risk-based
capabilities and integration of
acquisitions, reinforcing our strategic
focus on advancing our enterprise
flywheel for growth
• 	CarelonRx operating revenue includes
growth in adjusted scripts and
contribution from recent acquisitions in
pharmacy services; adjusted operating
margin consistent with our long-term
target range
• 	Carelon Services operating revenue
expansion of over 60% reflects the
addition of CareBridge and the scaling
of risk-based solutions; adjusted
operating margin reflects the dilutive
effect of CareBridge, offset by improved
Carelon Health performance
1Q 2025 Results
Change (%/bps)	1Q 2024	1Q 2025	Carelon
37.9%	$12.1B	$16.7B	Operating Revenue 1
27.5%	$0.9B	$1.1B	Adjusted Operating Gain1,2
(50) bps	7.1%	6.6%	Adjusted Operating Margin 1,2
9.0%	77.0M	83.9M	Adjusted Scripts
(3.3%)	102.9M	99.5M	Consumers Served
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “Reportable Segment Highlight Details” on slide 14 herein.
Health Services

-- 6 of 15 --

77
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Approximately 46M medical members
balanced across commercial,
Medicaid and Medicare, leveraging
the assets and capabilities of Carelon
to accelerate growth
As an integrated portfolio of whole
health solutions serving approximately
100M consumers, Carelon connects care
across physical, behavioral, social,
home health, and pharmacy needs to
bend the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 7 of 15 --

88
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1
Long-Term Growth Algorithm
Revenue Growth
High Single Digit CAGR1
Adjusted Operating Margin
Expanding to 6.5% - 7.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by membership growth, cost trend, geographic
expansion, and growth in specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk-based revenue growth including M&A
CarelonRx
Low Double Digit CAGR
Driven by script volumes and drug mix
Transforming our business
processes by leveraging new
technologies across operations
Commitment to operating
efficiency and optimizing core
businesses
Effective medical management
Underwriting discipline
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
Targeting at least 12% average annual growth in Adjusted Diluted EPS
1. 	CAGR = Compound Annual Growth Rate Target.

-- 8 of 15 --

99
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2024 	Target
$175B
High Single
Digit CAGR1
2024 	Target
Elevance Health
5.8%
Mid to High
Single Digit
2024 	Target
$54B
Mid Teens
CAGR1
2024 	Target
Carelon 2
4.2%
5.5% – 6.5%
2024 	Target
$150B
Mid to High
Single Digit
CAGR1
2024 	Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted 3
Operating
Margin
Revenue
(in billions)
1. 	CAGR = Compound Annual Growth Rate Target.
2. 	The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx,
and (ii) a high teens to low twenties revenue CAGR and mid to high single digit operating margin for Carelon Services.
3. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 9 of 15 --

10
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and
estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements
regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could
cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our
reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the
extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties
include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large
scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws
or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application;
the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations,
claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial
intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that
may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic
growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed
thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to
revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits
or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and
services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS
Health, L.L.C.; the effects of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and
strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in
the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our
common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness
and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings;
events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our
international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

-- 10 of 15 --

11
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on the last slide of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 11 of 15 --

12	12
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share
Three Months Ended Mar 31
Change	2024	2025	(In millions, except per share data)
(2.8)%	$2,246	$2,183	Shareholders' net income
Add / (Subtract):
161	464	Net losses on financial instruments
116	155	Amortization of other intangible assets
52	80	Transaction and integration related costs1
2	5	Litigation and settlement expenses1
60	—	Business dispositions and related items 2
(4)	—	Business optimization charges 1
(96)	(168)	Tax impact of non-GAAP adjustments
291	536	Net adjustment items
7.2%	$2,537	$2,719	Adjusted shareholders' net income
0.2%	$9.59	$9.61	Shareholders’ earnings per diluted share
Add / (Subtract):
$0.69	$2.04	Net losses on financial instruments
0.50	0.68	Amortization of other intangible assets
0.22	0.35	Transaction and integration related costs1
0.01	0.02	Litigation and settlement expenses1
0.26	—	Business dispositions and related items 2
(0.02)	—	Business optimization charges 1
(0.41)	(0.74)	Tax impact of non-GAAP adjustments
1.24	$2.36	Net adjustment items
10.5%	$10.83	$11.97	Adjusted shareholders’ earnings per diluted share
Three Months Ended Mar 31
Change	2024	2025	(In millions)
(4.8)%	$2,939	$2,797	Income before income tax expense
(465)	(590)	Net investment income
161	464	Net losses on financial instruments
265	344	Interest expense
116	155	Amortization of other intangible assets
5.1%	$3,016	$3,170	Reportable segments operating gain
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
3. 	Totals may not foot due to rounding.

-- 12 of 15 --

13	13
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2025 Outlook
Three Months Ended Mar 31
Change	2024	2025	(In millions)
8.5%	$4,886	$5,300	Operating expense
Add / (Subtract):
(52)	(80)	Transaction and integration related costs1
(2)	(5)	Litigation and settlement expenses1
(60)	—	Business dispositions and related items 2
4	—	Business optimization charges 1
(110)	(85)	Net adjustment Items
9.2%	$4,776	$5,215	Adjusted operating expense
15.4%	$42,273	$48,765	Operating revenue
(70) bp	11.6%	10.9%	Operating expense ratio
(60) bp	11.3%	10.7%	Adjusted operating expense ratio
Three Months Ended Mar 31
Change	2024	2025	(In millions)
5.1%	$3,016	$3,170	Reportable segments operating gain
Add / (Subtract):
52	80	Transaction and integration related costs1
2	5	Litigation and settlement expenses1
60	—	Business dispositions and related items 2
(4)	—	Business optimization charges 1
110	85	Net adjustment Items
4.1%	$3,126	$3,255	Reportable segments adjusted operating gain
Full Year 2025
Outlook
$28.30 to $29.00	Shareholders’ earnings per diluted share
Add / (Subtract):
$3.21	Net losses on financial instruments3
$2.98	Amortization of other intangible assets3
$1.35	Transaction and integration related costs1, 3
$0.06	Litigation and settlement expenses1, 3
Approximately ($1.75)	Tax impact of non-GAAP adjustments3
$5.85	Net adjustment items
$34.15 to $34.85	Adjusted shareholders’ earnings per diluted share
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
3. 	Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.

-- 13 of 15 --

14	14
Elevance Health
Reportable Segment Highlight Details
Three Months Ended Mar 31
Change	2024	2025	(In millions, Unaudited)
Operating Revenue
11.2%	$37,258	$41,431	Health Benefits
25.4%	8,067	10,116	CarelonRx
63.0%	4,009	6,536	Carelon Services
29.9%	127	165	Corporate & Other
NM 5	(7,188)	(9,483)	Eliminations
15.4%	$42,273	$48,765	Total Operating Revenue1
Operating Gain (Loss)
(3.1)%	$2,287	$2,217	Health Benefits 2
15.1%	523	602	CarelonRx
69.3%	290	491	Carelon Services2
NM 5	(84)	(140)	Corporate & Other 2,3
5.1%	$3,016	$3,170	Total Operating Gain1,4
Operating Margin
(70) bp	6.1%	5.4%	Health Benefits
(50) bp	6.5%	6.0%	CarelonRx
30 bp	7.2%	7.5%	Carelon Services
(60) bp	7.1%	6.5%	Total Operating Margin1
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	Operating Gain for the three months ended March 31, 2024, included $60 million of 2024 business dispositions and related items; including $44 million for the Carelon Services segment; and $16 million for the Health Benefits
segment. Operating Gain for the three months ended March 31, 2024, included $52 million of transaction and integration related costs, $2 million of litigation and settlement expenses, and ($4) million of business optimization
charges, all of which reside in the Corporate & Other reportable segment.
3. 	Operating Gain for the three months ended March 31, 2025, included $80 million of transaction and integration related costs and $5 million of litigation and settlement expenses, which reside in the Corporate & Other reportable
segment.
4. 	Operating Gain for the three months ended March 31, 2025, and March 31, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on slides 12 and 13 herein.
5. 	"NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).

-- 14 of 15 --



-- 15 of 15 --